AbbVie Inc (NYSE: ABBV) was upgraded by analysts at Piper Jaffray Companies from a "neutral" rating to an "overweight" rating.
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- Klinefelter Syndrome Treatment Market Share, Size, Global Key Players, Industry Demand, Regional Analysis and Forecast 2027 [MarketWatch]MarketWatch
- AbbVie Inc. (<a href="https://www.marketbeat.com/stocks/NYSE/ABBV/price-target/">NYSE: ABBV</a>) had its price target raised by analysts at Citigroup Inc. from $125.00 to $155.00.MarketBeat
- Uterine Fibroid Treatment Device Market Research Report by Technology, by Mode of Treatment, by Region - Global Forecast to 2027 - Cumulative Impact of COVID-19 [MarketWatch]MarketWatch
- AbbVie Inc. (<a href="https://www.marketbeat.com/stocks/NYSE/ABBV/price-target/">NYSE: ABBV</a>) had its price target raised by analysts at Morgan Stanley from $124.00 to $142.00. They now have an "overweight" rating on the stock.MarketBeat
- Allergan Aesthetics Announces Open Casting Call for BOTOX® Cosmetic (onabotulinumtoxinA)PR Newswire
ABBV
Earnings
- 10/29/21 - Beat
ABBV
Sec Filings
- 1/5/22 - Form 4
- 1/4/22 - Form 4
- 1/4/22 - Form 4
- ABBV's page on the SEC website